The SYNCHRONIZE-MASLD trial met its co-primary endpoints over 48 weeks, with a substantial majority achieving meaningful liver fat reduction and a notable portion normalizing liver fat, reinforcing survodutide’s potential in MASLD.

In the same program, Boehringer Ingelheim’s survodutide showed strong fat loss effects, including large reductions in visceral fat and liver fat, while lean mass loss remained limited at the highest dose, indicating fat-driven weight loss and improved metabolic health.

Survodutide remains investigational and is not approved; it carries several regulatory designations such as FDA Breakthrough Therapy and Fast Track, with EMA PRIME designation and Breakthrough designations in China and Taiwan.

SYNCHRONIZE-1, involving 725 adults without type 2 diabetes, tested weekly doses of 3.6 mg or 6.0 mg against placebo over 76 weeks, with primary endpoints including percentage weight change and a high threshold for weight loss achievement.

Global Phase III programs LIVERAGE and LIVERAGE-Cirrhosis are evaluating survodutide in MASLD-related fibrosis at advanced stages, signaling broadening trials in MASLD-related liver disease.

The drug is licensed from Zealand Pharma to Boehringer Ingelheim, which leads global development and commercialization; Zealand stands to royalties and milestone payments totaling up to mid-to-high single digits and up to EUR 315 million.

Positive Phase III results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented at major conferences and published in NEJM and Nature Medicine, underscoring robust data for survodutide.

The releases contextualize MASLD/MASH epidemiology and emphasize the growing need for treatments that address visceral and liver fat and overall metabolic health.

Safety aligns with GLP-1–based therapies, with gastrointestinal events being the most common adverse effects and discontinuation around 19% at higher doses, but no new safety signals.

Beyond weight loss, survodutide aims to improve metabolic health by addressing visceral and liver fat, inflammation, and fibrosis, with outlines for future trials and global development plans.

The program combines GLP-1–mediated appetite suppression with glucagon-driven hepatic fat reduction, aiming to treat obesity-related metabolic dysfunction and liver fat accumulation across broader populations.

The message reiterates that survodutide is investigational, with safety profiles consistent with GLP-1 therapies and similar discontinuation rates at higher doses.